Promises and limitations of nanoparticles in the era of cell therapy: Example with CD19-targeting chimeric antigen receptor (CAR)-modified T cells

Abstract : A number of nanoparticles has been developed by chemists for biomedical applications to meet imaging and targeting needs. In parallel, adoptive T therapy with chimeric antigen receptor engineered T cells (CART cells) has recently held great promise in B-cell malignancy treatments thanks to the development of anti-CD19 CAR T cells. Indeed, CD19 is a reliable B cell marker and a validated target protein for therapy. In this perspective article, we propose to discuss the advantages, limits and challenges of nanoparticles and CAR T cells, focusing on CD19 targeting objects: anti-CD19 nanoparticles and anti-CD19 CAR T cells, because those genetically-modified cells are the most widely developed in clinical setting. In the first part, we will introduce B cell malignancies and the CD19 surface marker. Then we will present the positioning of nanomedicine in the topic of B cell malignancy, before exposing CAR T technology. Finally, we will discuss the complementary approaches between nanoparticles and CAR T cells.
Type de document :
Article dans une revue
International Journal of Pharmaceutics, Elsevier, 2017, 532 (2), pp.813-824. 〈10.1016/j.ijpharm.2017.07.075〉
Liste complète des métadonnées

Littérature citée [4 références]  Voir  Masquer  Télécharger

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01617055
Contributeur : Laurent Jonchère <>
Soumis le : mardi 24 octobre 2017 - 12:02:41
Dernière modification le : vendredi 25 mai 2018 - 01:28:16
Document(s) archivé(s) le : jeudi 25 janvier 2018 - 12:58:11

Fichier

CD19-pour-HAL.pdf
Fichiers produits par l'(les) auteur(s)

Identifiants

Citation

Helene Jakobczyk, Flavien Sciortino, Soizic Chevance, Fabienne Gauffre, Marie-Bérengère Troadec. Promises and limitations of nanoparticles in the era of cell therapy: Example with CD19-targeting chimeric antigen receptor (CAR)-modified T cells. International Journal of Pharmaceutics, Elsevier, 2017, 532 (2), pp.813-824. 〈10.1016/j.ijpharm.2017.07.075〉. 〈hal-01617055〉

Partager

Métriques

Consultations de la notice

171

Téléchargements de fichiers

33